Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
This biotech innovator could be in only the early chapters of its success story.
Overview
To say that Argenx (NASDAQ: ARGX) is growing is an understatement. The drugmaker has delivered an impressive 18 consecutive quarters of revenue growth. Its sales soared 60% year over year in the second quarter of 2026 and 17% sequentially.
Investors have recognized Argenx's success. The biotech stock is handily beating the overall market so far this year and has more than doubled over the last three years. But is Argenx still underrated?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.